Sequential Use of Systemic Therapy With Locoregional Therapy for Hepatocellular Carcinoma in Japan: Analyses of Real‐World Data Based on a Health Claims Database Authors: Junichi Shindoh, Sachiyo Shirakawa, Ikumi Takashima, Daisuke Kawai, Kenichiro Nishida, Hiroshi Kitagawa Published: 2026 ABSTRACT ABSTRACTAimThe treatment of hepatocellular carcinoma (HCC) in Japan is driven by locoregional therapies (LRTs). However, the treatment landscape in the era of systemic targeted therapies and immunotherapies is not well understood. We investigated the real‐world treatment patterns of combined LRT and systemic therapy in Japan.MethodsWe performed analyses of the Medical Data Vision (MDV) database using data for patients with a recorded diagnosis of HCC and at least one record of a first LRT (January 1, 2020–December 31, 2022; hepatectomy, transarterial chemoembolization [TACE], radiation therapy [RT], ablation, or hepatic arterial infusion chemotherapy [HAIC]) after the record of HCC diagnosis. We examined the use of preceding systemic therapy (PSysT), maintenance treatment (MT), and next treatments.ResultsAmong 15,285 patients, hepatectomy, TACE, RT, ablation, and HAIC were performed in 4506, 6389, 991, 3351, and 48 patients, respectively. Few patients received PSysT, including lenvatinib (by LRT: 0.93%–12.50%) and atezolizumab + bevacizumab (by LRT: 0.29%–4.94%). Only TACE with PSysT increased slightly during the study period. MT was infrequent. Cumulative incidence of next treatment at 6 months varied by type of first LRT, ranging from 6.61% following hepatectomy to 45.06% following HAIC.ConclusionLRT alone remained the standard approach for treating HCC in Japan in 2020–2022. The type and duration of therapies used before or after first LRT varied, suggesting a lack of standardized protocols. A clear strategy is needed to evaluate and establish appropriate LRT‐based combination therapies for HCC, considering the unmet medical needs identified in this study. Abbreviations Diagnosis Procedure Combination first locoregional therapy hepatic arterial infusion chemotherapy hepatocellular carcinoma interquartile range locoregional therapy Medical Data Vision maintenance systemic therapy maintenance treatment Per‐Diem Payment System preceding systemic therapy radiofrequency ablation radiation therapy stereotactic body radiation therapy transarterial chemoembolization Introduction Liver cancer was the third most common cause of cancer‐related deaths globally in 2020, with age‐standardized rates of 9.5 and 8.7 per 100,000 people for new cases and deaths, respectively [1, 2]. In Japan, liver cancer, including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma, is the fifth most common cause of cancer death, with an incidence of 27.5 cases per 100,000 people annually (in 2022) and a mortality of approximately 18.9 per 100,000 people (in 2023) [3]. HCC constituted the majority of cases, comprising 90.1% of the histological subtypes in Japan [4]. The treatment strategy for HCC in Japan was dominated by locoregional therapies (LRTs), including hepatectomy, ablation, artery‐directed therapies (e.g., transarterial chemoembolization [TACE] and hepatic arterial infusion chemotherapy [HAIC]), and radiation therapy (RT), until the recent introduction of systemic therapies, including targeted therapies and immunotherapies [5, 6]. Liver transplantation, particularly deceased donor transplantation, is rarely performed in Japan due to a shortage of donors, and there are challenges to wider application of living donor liver transplantation [7]. According to the latest report of the Japanese Liver Cancer Registry, among 17,058 patients who were newly diagnosed with HCC in the period 2016–2017, systemic therapies were used as first‐line therapy in only 1.7% of patients, whereas 89.4% of patients received LRT [8]. Notably, TACE was the most frequently used option for all lines of sequential therapy, and it was repeatedly used in subsequent lines of therapy [9], reflecting its central role in managing HCC, especially for intermediate‐stage disease, in Japan. In 2009, sorafenib was approved as the first molecular therapy for unresectable HCC in Japan (2007 in the US and Europe). Nine drugs, including multi‐kinase inhibitors and immune checkpoint inhibitors, are currently available for treating advanced HCC in Japan. The novel pharmacological therapies demonstrated efficacy in patients with advanced disease, thereby raising expectations for an additional benefit when combined with LRT. Systemic therapies may be combined with LRTs, including TACE [10], HAIC [11], radiofrequency ablation (RFA) [12], and stereotactic body RT (SBRT). In the RTOG 1112 phase 3 study, the combination of SBRT with sorafenib resulted in more favorable overall survival than sorafenib alone [13]. Several Japanese phase 2 studies are also exploring the role of systemic therapies as part of preoperative therapy for patients with potential borderline‐resectable HCC [14, 15, 16]. Furthermore, recent studies have reported evidence supporting the combination of TACE with systemic therapy or are currently investigating this approach [10, 17, 18, 19]. Considering the available evidence and ongoing studies, a combination of LRT and systemic therapy, whether administered before LRT as preceding systemic therapy (PSysT) or after LRT as maintenance systemic therapy (MSysT), is becoming an increasingly important treatment strategy for HCC [20]. Despite the gradual increase in clinical use of combining LRT and systemic therapy for the treatment of HCC in Japan, there remains limited evidence from clinical trials documenting the effectiveness and safety of this approach. Moreover, few real‐world studies have examined the treatment patterns, patient characteristics, and outcomes after new agents and combination therapies have been approved and launched for unresectable advanced HCC. There are limited references available for optimizing treatment. Therefore, this study sought to evaluate the recent real‐world treatment patterns of combined LRT and systemic therapy in Japan. The results of this study are expected to provide insight into the treatment patterns related to LRT and systemic therapies in the clinical situation where the optimal treatment strategy for HCC involving LRT has not yet been established. We also discuss the remaining clinical questions and unmet needs to be addressed in the future. Methods Data Source We used a Japanese database managed by Medical Data Vision Co., Ltd. (MDV). This database contains Diagnosis Procedure Combination (DPC) data and administrative claims data from hospitals that utilize the DPC and Per‐Diem Payment System (PDPS), a Japanese prospective payment system for acute inpatient care (called DPC‐participating hospitals). The DPC data contain the patients' basic and clinical information, including date of birth, sex, discharge outcome, diagnosis, and treatment procedure [21]. As of April 2020, the payment system had been introduced to 1757 hospitals, covering about 54% of all general hospital beds in Japan [21]. Out of these, the MDV database contains the data for > 40 million patients from > 500 hospitals [22]. Study Design and Population We conducted a retrospective cohort study using the MDV database (April 2008 to March 2024). We included patients with a recorded diagnosis of HCC (International Classification of Diseases 10th Revision code C22.0) and at least one record of an LRT between January 1, 2020, and December 31, 2022, following the record of HCC diagnosis (Figure 1a). This is a prevalent cohort anchored at the first recorded LRT between January 1, 2020, and December 31, 2022. Prior LRTs within 2 years were excluded. Follow‐up continued until December 31, 2023, or the last available record. The LRTs considered in this study were hepatectomy, TACE, RT, ablation, and HAIC, which were defined using the procedure codes listed in Table S1. If two or more LRTs were recorded on the same day, the LRTs were prioritized in the order: hepatectomy, TACE, RT, ablation, HAIC. The index date was defined as the date of the first record of LRT (i.e., F‐LRT). Patients with any records of LRT during the look‐back period (2‐year period prior to the index date) and patients diagnosed with a malignancy other than HCC (C00–C75 and C81–C96, excluding C22.0) within 5 years prior to the F‐LRT were subsequently excluded. The remaining eligible patients were divided into five cohorts according to the F‐LRT (Figure 1b). (a) Study design and patient eligibility. (b) Definitions of treatment patterns. The PSysT period was defined as days −90 to −1, the MT period as days 0 to 60, and the next treatment period as days 61 to 180. F‐LRT, first locoregional therapy; HAIC, hepatic arterial infusion chemotherapy; HCC, hepatocellular carcinoma; ICD10, International Classification of Diseases, 10th revision; LRT, locoregional therapy; MT, maintenance treatment; PSysT, preceding systemic therapy; RT, radiation therapy; TACE, transarterial chemoembolization. Patient characteristics at the index date were defined using the information retrieved in the look‐back period. The patients were followed from the index date to the latest date of the patient records, the date of death, or the end date of the follow‐up period (December 31, 2023), whichever came first. Therapies for HCC We focused on the systemic therapies used prior to the F‐LRT (referred to as PSysT), and systemic therapies or alternative LRTs used following the F‐LRT (referred to as maintenance treatment [MT] and next treatment). The PSysT was defined as any systemic HCC therapy with a last administration/prescription in the window of days −90 to −1 prior to the F‐LRT (index date = day 0). The PSysT regimen was assigned as the agent(s) with the last prescription date closest to day −1 in this window. MT was defined as systemic therapy initiated within days 0 to 60 after the F‐LRT. If the same LRT as the F‐LRT was repeated within 90 days, it was classified as part of F‐LRT (not MT). The ‘next treatment’ was defined as the first systemic therapy or LRT recorded within days 61 to 180 after the F‐LRT; MT episodes continuing into days 61 to 180 were not reclassified as next treatment. Days when systemic therapy and LRT were recorded together were flagged as multiple therapy. The clinical intent and disease stage were not recorded in the database and could not be used to ascertain the reason for selecting certain treatments. The eligible therapies are further defined in Figure 1b and Table S2. All systemic therapies and LRTs were identified using relevant clinical codes (Tables S1 and S3). The types of regimens used as PSysT were defined as the regimen with the prescription date closest to the index date during the PSysT period (Figure 1a,b). The eligible regimens were lenvatinib, atezolizumab + bevacizumab, sorafenib, regorafenib, ramucirumab, cabozantinib, pembrolizumab, and multiple systemic regimens (two or more different systemic therapies prescribed on the same day). Patients with no prescription records for a systemic therapy during the PSysT period were categorized as no PSysT. The types of regimens used as MT were defined as the regimen (excluding the F‐LRT) with the prescription date for a MSysT or LRT closest to the index date during the MT period (Figure 1a,b). The eligible regimens included LRT (hepatectomy, TACE, RT, ablation, and HAIC), systemic therapy (lenvatinib, atezolizumab + bevacizumab, sorafenib, regorafenib, ramucirumab, cabozantinib, pembrolizumab, or durvalumab), and multiple therapies (two or more different systemic therapies or LRT + systemic therapy were prescribed on the same day). Patients with no prescriptions for a MT were categorized as either follow‐up after the MT period, death during the MT period, or lost to follow‐up during the MT period. Multiple sessions of the F‐LRT, defined as the administration of the same LRT within 90 days after the index date, were not considered as a MT. The types of regimens used as the next treatment were defined as the regimen with the prescription date of systemic therapy or LRT closest to 61 days after the index date. The eligible regimens were similar to those for MT (Table S2). If the duration of the MT crossed into the next treatment period (i.e., days 61 to 180), the MT was not considered as a next treatment. Multiple sessions of the F‐LRT were not considered as a next treatment. Outcomes The primary outcome was the number and proportion of patients with a record of each PSysT regimen by each F‐LRT group. The secondary outcomes included the following for each F‐LRT group: (1) duration of each PSysT; (2) the number and proportion of patients with each therapy in each phase of sequential treatment, including PSysT, F‐LRT, and MT; and (3) the duration of each MSysT. The duration of each PSysT was the time from the treatment start date, which was defined as the earliest prescription date of each systemic therapy during the PSysT period, to the treatment end date, which was the prescription date of the systemic therapy closest to the index date. If the PSysT was an oral drug (lenvatinib, sorafenib, regorafenib, or cabozantinib), the duration was added to the number of prescription days in the last prescription. If the prescription interval for the same systemic chemotherapy was ≥ 60 days, the earlier prescription date was not considered as the treatment start date. For the duration of each MSysT, the start date was defined as the prescription (administration) date used to define the MT. The end date of each MSysT was defined as the prescription date of the systemic therapy (same regimen as the MSysT) closest to the maximum follow‐up date. The end date was added to the number of prescription days at the original end date. If the prescription interval for the same systemic chemotherapy was ≥ 60 days, the latest prescription date was not considered as the end date. If the PSysT was an oral drug (lenvatinib, sorafenib, regorafenib, or cabozantinib), the treatment duration was added to the number of prescription days in the last prescription. If the MT was categorized as multiple therapies and different systemic therapy regimens were prescribed, the treatment duration was calculated for the systemic therapy with the longer duration. As an exploratory outcome, we determined the time from the F‐LRT to the next treatment. Patients were censored if they had a last record prior to initiating the next treatment or no initiation of a next treatment within 180 days after the F‐LRT. Deaths were not censored and were considered a competing risk. Statistical Analysis All analyses were performed for patients who met the eligibility criteria. Patient characteristics were summarized using the mean, standard deviation, median, minimum, and maximum for continuous variables, and the number and percent for categorical variables. The frequencies of the treatment regimens and the treatment patterns were summarized using the number and percent of patients. The treatment pathway (PSysT, F‐LRT, and MT) was visualized using a Sankey diagram. Among patients with systemic therapy, the durations of PSysT and MSysT were determined for patients with records of each type of systemic therapy, using the mean, standard deviation, median, minimum, maximum, and quartiles (Q1–Q3). The cumulative incidence of next treatment was estimated using the cumulative incidence function to consider the competing risk of death. One month was defined as 30 days. No multivariable adjustment was performed. Missing data were not imputed. All analyses were performed using SAS Viya 3.5 (SAS Institute Inc., Cary, NC, USA). Results Patient Disposition Between April 2008 and March 2024, data for 162,804 patients with a recorded diagnosis of HCC were retrieved from the MDV database (Figure S1). Of these, 24,584 underwent LRT between January 1, 2020, and December 31, 2022. After excluding patients with prior LRT or other malignancy, 15,285 patients were eligible for the study. TACE was the most common F‐LRT, accounting for 6389 patients, followed by hepatectomy in 4506 patients, ablation in 3351 patients, RT in 991 patients, and HAIC in 48 patients. Patient Characteristics Patient characteristics according to the F‐LRT at the index date are presented in Table 1. Across all F‐LRTs, most patients were male (66.0% to 79.2%) with median ages ranging from 71.0 to 76.0 years. Among patients who received the F‐LRTs with available data, 16.3% to 35.0% of patients were positive for hepatitis C, and 10.0% to 18.9% were positive for hepatitis B. The majority of patients in each F‐LRT group had not received any previous therapies except for PSysT. TABLE 1Characteristics of patients who underwent F‐LRT for HCC.Hepatectomy n = 4506TACE n = 6389RT n = 991Ablation n = 3351HAIC n = 48Age, years, median (range)73.0 (11–98)76.0 (27–100)74.0 (35–96)74.0 (29–100)71.0 (51–90)Age ≥ 75 years1803 (40.0)3551 (55.6)490 (49.4)1612 (48.1)15 (31.3)SexMale3394 (75.3)4619 (72.3)753 (76.0)2212 (66.0)38 (79.2)Female1112 (24.7)1770 (27.7)238 (24.0)1139 (34.0)10 (20.8)Liver‐related comorbiditiesHepatitis C1028 (22.8)1874 (29.3)162 (16.3)1173 (35.0)8 (16.7)Hepatitis B852 (18.9)923 (14.4)99 (10.0)628 (18.7)7 (14.6)Liver cirrhosis739 (16.4)2076 (32.5)187 (18.9)1128 (33.7)16 (33.3)Hepatic steatosis232 (5.1)233 (3.6)15 (1.5)182 (5.4)0Non‐alcoholic steatohepatitis97 (2.2)166 (2.6)11 (1.1)141 (4.2)0Alcoholic hepatitis52 (1.2)70 (1.1)7 (0.7)31 (0.9)0Previous therapies a Lenvatinib7 (0.2)77 (1.2)19 (1.9)12 (0.4)5 (10.4)Atezolizumab + bevacizumab4 (0.1)56 (0.9)18 (1.8)6 (0.2)3 (6.3)Sorafenib019 (0.3)12 (1.2)1 (0.03)1 (2.1)Regorafenib09 (0.1)6 (0.6)1 (0.03)0Ramucirumab05 (0.1)3 (0.3)00Cabozantinib04 (0.1)4 (0.4)00No previous treatment4495 (99.8)6219 (97.3)929 (93.7)3331 (99.4)39 (81.3) Note: Values are median (range) and IQR, with the number of patients who received each regimen.Abbreviations: F‐LRT, first locoregional therapy; HAIC, hepatic arterial infusion chemotherapy; IQR, interquartile range; MSysT, maintenance systemic therapy; N/A, not applicable; RT, radiation therapy; TACE, transarterial chemoembolization. a Systemic therapy for HCC within 2 years before the first LRT (index date) other than preceding systemic therapy. Characteristics of patients who underwent F‐LRT for HCC. Note: Values are median (range) and IQR, with the number of patients who received each regimen. Abbreviations: F‐LRT, first locoregional therapy; HAIC, hepatic arterial infusion chemotherapy; IQR, interquartile range; MSysT, maintenance systemic therapy; N/A, not applicable; RT, radiation therapy; TACE, transarterial chemoembolization. Systemic therapy for HCC within 2 years before the first LRT (index date) other than preceding systemic therapy. Positioning of PSysT Most patients had no PSysT for HCC, ranging from 72.92% in the HAIC group to 98.76% in the hepatectomy group (Table 2). Among patients who received a PSysT, the most frequently used systemic therapies in each F‐LRT group were lenvatinib (0.93% to 12.50%) and atezolizumab + bevacizumab (0.29% to 4.94%). TABLE 2Proportion of patients with the specified PSysT according to the type of F‐LRT.Hepatectomy n = 4506TACE n = 6389RT n = 991Ablation n = 3351HAIC n = 48Lenvatinib43 (0.95)254 (3.98)59 (5.95)31 (0.93)6 (12.50)Atezolizumab + bevacizumab13 (0.29)83 (1.30)49 (4.94)10 (0.30)2 (4.17)Sorafenib041 (0.64)11 (1.11)4 (0.12)1 (2.08)Regorafenib07 (0.11)5 (0.50)02 (4.17)Ramucirumab05 (0.08)5 (0.50)1 (0.03)0Cabozantinib012 (0.19)5 (0.50)1 (0.03)2 (4.17)Pembrolizumab, n (%)00000Multiple regimens, n (%)00000No PSysT, n (%)4450 (98.76)5987 (93.71)857 (86.48)3304 (98.60)35 (72.92)Abbreviations: F‐LRT, first locoregional therapy; HAIC, hepatic arterial infusion chemotherapy; N/A, not applicable; PSysT, preceding systemic therapy; RT, radiation therapy; TACE, transarterial chemoembolization. Proportion of patients with the specified PSysT according to the type of F‐LRT. Abbreviations: F‐LRT, first locoregional therapy; HAIC, hepatic arterial infusion chemotherapy; N/A, not applicable; PSysT, preceding systemic therapy; RT, radiation therapy; TACE, transarterial chemoembolization. Table 3 shows that the distribution of the duration of PSysT varied among the types of systemic therapies combined with F‐LRT. For lenvatinib, the median (interquartile range [IQR]) duration ranged from 58.0 (48.0–120.0) days to 125.0 (30.0–347.0) days, and that for atezolizumab + bevacizumab ranged from 68.0 (22.0–111.0) days to 235.5 (225.0–246.0) days. TABLE 3Duration of PSysT according to the type of F‐LRT.Hepatectomy n = 4506TACE n = 6389RT n = 991Ablation n = 3351HAIC n = 48Lenvatinib n 4325459316Median (range) a 58.0 (4–632)80.5 (1–729)63.0 (1–724)125.0 (5–712)80.0 (14–281)(IQR) a (48.0–120.0)(18.0–203.0)(14.0–316.0)(30.0–347.0)(44.0–143.0)Atezolizumab + bevacizumab n 138349102Median (range) a 127.0 (1–277)112.0 (1–546)68.0 (1–287)95.0 (1–309)235.5 (225–246)(IQR) a (85.0–197.0)(46.0–190.0)(22.0–111.0)(56.0–172.0)(225.0–246.0)Sorafenib n 0411141Median (range) a N/A133.0 (7–729)43.0 (1–726)193.0 (55–658)78.0 (N/A)(IQR) a N/A(53.0–595.0)(7.0–98.0)(76.5–473.0)(N/A)Regorafenib n 07502Median (range) a N/A95.0 (7–213)77.0 (14–196)N/A85.0 (9–161)(IQR) a N/A(21.0–210.0)(14.0–79.0)N/A(9.0–161.0)Ramucirumab n 05510Median (range) a N/A99.0 (16–179)43.0 (15–107)372.0 (N/A)N/A(IQR) a N/A(57.0–99.0)(15.0–57.0)(N/A)N/ACabozantinib n 012512Median (range) a N/A35.5 (15–251)25.0 (7–199)19.0 (N/A)13.5 (11–16)(IQR) a N/A(26.5–120.0)(20.0–68.0)(N/A)(11.0–16.0) Note: Values are median (range) and IQR, with the number of patients who received each regimen.Abbreviations: F‐LRT, first locoregional therapy; HAIC, hepatic arterial infusion chemotherapy; IQR, interquartile range; MSysT, maintenance systemic therapy; N/A, not applicable; RT, radiation therapy; TACE, transarterial chemoembolization. a Calculated for patients with records of each preceding systemic therapy. Duration of PSysT according to the type of F‐LRT. Note: Values are median (range) and IQR, with the number of patients who received each regimen. Abbreviations: F‐LRT, first locoregional therapy; HAIC, hepatic arterial infusion chemotherapy; IQR, interquartile range; MSysT, maintenance systemic therapy; N/A, not applicable; RT, radiation therapy; TACE, transarterial chemoembolization. Calculated for patients with records of each preceding systemic therapy. Treatment Patterns of F‐LRT and MT The Sankey diagram of treatment flow is presented in Figure 2. The numbers and percentages of patients at each node are listed in Table S4. There were 12,297 (80.45%) patients with no MT and 999 (6.54%) patients were lost to follow‐up during the MT period. The majority of the patients who received MT received TACE as F‐LRT. Of note, ablation was the most common MT (5.76%), followed by lenvatinib (2.67%) and atezolizumab + bevacizumab (1.39%). Sankey diagram of the treatment flow from PSysT to MT. Values are shown as the n (%) of patients for each node, using 15,285 as the denominator. The numbers of patients at each node are presented in detail in Table S4. F‐LRT, first locoregional therapy; HAIC, hepatic arterial infusion chemotherapy; MT, maintenance treatment; PSysT, preceding systemic therapy; RT, radiation therapy; TACE, transarterial chemoembolization. Regarding treatment patterns (Table S5), nearly all of the patients in the hepatectomy (97.58%) and ablation (96.93%) groups underwent F‐LRT alone, without PSysT and/or MT. In contrast, approximately three‐quarters of the patients in the TACE (74.82%) and RT (76.29%) groups, and half of the patients in the HAIC group (56.25%) received F‐LRT alone. MT and/or PSysT were more common in the TACE, RT, and HAIC groups. Figure 3 shows the annual changes in treatment patterns for each F‐LRT in the years 2020–2022 as the category counts and percentages. There were no marked changes over time in the percentages of patients who underwent F‐LRT alone in the hepatectomy, ablation, and RT groups. In the TACE cohort, TACE alone decreased from 76.22% to 71.80%, PSysT + TACE increased from 1.93% to 4.20%, and PSysT + TACE + MT rose from 2.95% to 5.22%. Annual changes in treatment patterns according to type of F‐LRT for the years 2020, 2021, and 2022. F‐LRT, first locoregional therapy; HAIC, hepatic arterial infusion chemotherapy; MT, maintenance treatment; PSysT, preceding systemic therapy; RT, radiation therapy; TACE, transarterial chemoembolization. Among patients who received MSysT, the distribution of the duration varied according to the type of therapy (Table 4). Among patients who received TACE as the F‐LRT (462 patients), the most common regimens were lenvatinib (287 patients) and atezolizumab + bevacizumab (119 patients). The median (IQR) durations of these regimens were 42.0 (23.0–56.0) days and 21.0 (1.0–22.0) days, respectively. The within‐patient concordance between PSysT and MSysT regimens could not be comprehensively assessed beyond descriptive counts due to the small numbers of patients and heterogeneity. TABLE 4Duration of MSysT according to the type of F‐LRT.Hepatectomy n = 28TACE n = 462RT n = 169Ablation n = 47HAIC n = 7Lenvatinib n 1628772312Median (range) a 28.0 (1–69)42.0 (1–98)39.0 (3–81)48.0 (2–84)37.0 (24–50)(IQR) a (18.0–33.0)(23.0–56.0)(26.0–54.0)(22.0–57.0)(24.0–50.0)Atezolizumab + bevacizumab n 1211968121Median (range) a 1.0 (1–22)21.0 (1–45)22.0 (1–50)22.0 (1–45)1.0 (N/A)(IQR) a (1.0–11.5)(1.0–22.0)(1.0–43.0)(1.0–39.0)N/ASorafenib n 0331933Median (range) a N/A28.0 (1–109)38.0 (3–77)56.0 (14–57)14.0 (9–37)(IQR) a N/A(17.0–49.0)(16.0–49.0)(14.0–57.0)(9.0–37.0)Regorafenib n 05401Median (range) a N/A21.0 (7–48)17.5 (7–42)N/A66.0 (N/A)(IQR) a N/A(14.0–35.0)(10.5–31.5)N/AN/ARamucirumab n 08310Median (range) a N/A8.0 (1–42)15.0 (15–15)1.0 (N/A)N/A(IQR) a N/A(1.0–38.5)(15.0–15.0)N/AN/ACabozantinib n 09300Median (range) a N/A21.0 (1–75)42.0 (32–68)N/AN/A(IQR) a N/A(14.0–32.0)(32.0–68.0)N/AN/APembrolizumab n 01000Median (range) a N/A29.0 (N/A)N/AN/AN/A(IQR) a N/AN/AN/AN/AN/A Note: Values are median (range) and IQR, with the number of patients who received each regimen.Abbreviations: F‐LRT, first locoregional therapy; HAIC, hepatic arterial infusion chemotherapy; IQR, interquartile range; MSysT, maintenance systemic therapy; N/A, not applicable; RT, radiation therapy; TACE, transarterial chemoembolization. a Calculated for patients with records of each MSysT. Duration of MSysT according to the type of F‐LRT. Note: Values are median (range) and IQR, with the number of patients who received each regimen. Abbreviations: F‐LRT, first locoregional therapy; HAIC, hepatic arterial infusion chemotherapy; IQR, interquartile range; MSysT, maintenance systemic therapy; N/A, not applicable; RT, radiation therapy; TACE, transarterial chemoembolization. Calculated for patients with records of each MSysT. Cumulative Incidence of Next Treatment The cumulative incidence curves for next treatment are plotted in Figure 4. The cumulative incidence of next treatment at 6 months was numerically lowest in the hepatectomy (6.61%) and ablation (11.55%) groups, and was higher in the TACE (29.61%), RT (26.25%), and HAIC (45.06%) groups. Cumulative incidence of next treatment according to the type of F‐LRT. The cumulative incidence of next treatment was estimated using the cumulative incidence function. The start date of the next treatment was defined as the prescription (administration) date closest to day 61 for systemic treatment or LRT within the period of days 61 to 180. Patients were censored before initiation of next treatment if the end of the study period was reached, day 180 after the F‐LRT, or loss to follow‐up. Deaths were not censored and were considered a competing risk. F‐LRT, first locoregional therapy; HAIC, hepatic arterial infusion chemotherapy; LRT, locoregional therapy; RT, radiation therapy; TACE, transarterial chemoembolization. The types of next treatment are listed in Table S6. The proportions of patients who received systemic therapies were 11.68%, 15.94%, and 29.17% in the TACE, RT, and HAIC groups, respectively, compared with 3.44% and 1.97% in the hepatectomy and ablation groups, respectively. The F‐LRT was repeated as a next treatment in some patients, mainly those who underwent TACE (10.49%) or ablation (5.55%). Few patients underwent hepatectomy or RT as a next treatment in any of the F‐LRT groups. Discussion This study was performed to investigate the recent treatment reality of patients with HCC who received F‐LRT between 2020 and 2022 using a nationwide hospital database in Japan. The primary outcome of our study was to determine the number and proportion of patients who received PSysT for each type of F‐LRT. Our analysis revealed that, generally, the majority of patients did not receive PSysT, regardless of the F‐LRT modality. We also visualized the different patterns and longitudinal reality of peri‐LRT systemic therapy among the LRT modalities. The results suggested that sequential systemic therapy was an emerging treatment option. The observed durations of PSysT and MSysT varied widely and there were some discrepancies compared with the data from early clinical trials [23, 24, 25, 26]. This suggested that robust evidence for peri‐LRT treatment is required to evaluate and establish appropriate LRT‐based combination therapies for HCC. LRTs were likely selected based on several factors, including tumor number and size, liver function reserve, and the patient's performance status that were not available in the database. Nevertheless, the LRTs could be divided into two categories: curative‐intent and non‐curative‐intent procedures. Here, we discuss the background and potential explanations for our results, as well as the future implications of curative‐ and non‐curative‐intent LRTs. Curative‐intent LRT (i.e., hepatectomy or ablation) alone was the standard of care during the study period, similar to a prior study showing that few patients received an additional treatment as PSysT [9, 27], most likely due to the empirical perception of marginal needs for additional treatments and limited evidence supporting the effectiveness of systemic therapy in this setting [23, 24, 25, 26]. Although the outcomes of neoadjuvant systemic therapy for patients with resectable HCC were reportedly favorable [28], further advances in additional therapies could be beneficial for such patients. Additionally, considering the potential for conversion surgery, additional therapies could offer a clinical benefit for patients with initially borderline‐resectable/unresectable disease [29]. The clinical environment and indications for this curative‐intent LRT may change in the future, especially for perioperative treatment, considering recent discussions regarding the concept of borderline‐resectable disease [30], and ongoing clinical trials of perioperative systemic therapy mainly using immune checkpoint inhibitors [31, 32]. Among non‐curative‐intent LRTs (i.e., TACE, HAIC, or RT), TACE was the most commonly used as F‐LRT. However, PSysT combined with non‐curative‐intent LRT, including TACE, was not yet a standard approach in clinical practice. One reason may relate to the traditional clinical use of TACE, where this procedure may be repeated in patients with recurrent and/or new lesions that could be controlled by LRT [5, 6]. We observed that the proportion of patients who received PSysT gradually increased during the study period, even in a clinical environment where robust evidence was not sufficient. In recent years, a novel, curative treatment strategy involving TACE combined with systemic therapy has emerged, and several data from clinical trials have been published [19, 33]. Further evidence is expected from the ongoing IMPACT trial, which is examining the role of atezolizumab + bevacizumab with vs. without TACE [29, 34]. In our study, we did not identify any baseline factors revealing target patients for systemic therapy combined with TACE. Further evidence supporting this approach is warranted. RT was the second most common LRT out of non‐curative‐intent LRTs, and nearly 15% of patients received peri‐LRT including PSysT. Although this proportion was higher than that observed for curative‐intent LRTs, the majority of patients who underwent RT did not receive PSysT. RT was possibly used as a palliative treatment for patients who may have been ineligible for other treatments, where additional systemic therapy may be challenging. However, the main reason for the low proportion of PSysT is likely due to limited evidence. Furthermore, the evidence for performing RT in patients with HCC is still not robust, and RT is weakly recommended in the Japanese guidelines for the treatment of HCC [5, 6]. The evolution of RT, including SBRT and particle therapy, might also have an impact on this result. The current guidelines [5, 6] recommend SBRT for patients with HCC ≤ 5 cm and < 4 nodules who are ineligible for surgery/ablation, and for patients with higher risk of recurrence, although this was not mentioned in the earlier guidelines that were likely used during the study period [35, 36]. Particle therapy is emerging as a treatment option for HCC, and reimbursement started in 2022 in Japan. These changes in RT modalities and availability might hinder efforts to develop evidence for combining systemic therapy with RT. In parallel with the advancements of RT and drug treatment for HCC, evidence demonstrating their effective combination is anticipated [37]. HAIC was rarely performed in this study cohort and peri‐LRT systemic therapy, including PSysT, was not used in nearly three‐quarters of all patients who underwent HAIC. Consequently, detailed evaluation of this cohort was not possible. Nevertheless, HAIC combined with systemic therapy is an emerging option that may become more widely used following the promising results of the LEOPARD trial [38]. The duration of PSysT varied regardless of the type of F‐LRT. Lenvatinib and atezolizumab + bevacizumab regimens were the most common peri‐LRT systemic therapies in patients who underwent non‐curative LRT. However, the duration of lenvatinib as post‐TACE MT was shorter than we expected, and the median duration of lenvatinib pre‐ and post‐TACE differed from the protocol used in the phase 2 study [10], which is cited as evidence to support this treatment approach. The observed ranges for the treatment duration were also broad, reflecting considerable heterogeneity in clinical practice. Meanwhile, there is no robust evidence supporting atezolizumab + bevacizumab as peri‐TACE systemic therapy, and its duration as peri‐TACE systemic therapy was short. These findings suggest that, in real‐world clinical settings, the administration of systemic therapies was coordinated based on the patient's clinical condition, such as performance status and liver function, rather than strict adherence to a specific protocol. The low proportion and the short duration of peri‐TACE systemic therapy suggest that it is not yet considered a standard of care, reflecting the limited and non‐robust clinical evidence supporting this treatment strategy during the study period. As mentioned above, evidence regarding combination systemic therapy is needed in order to optimize the treatment duration. In particular, it will be necessary to obtain more detailed clinical information, including patient background, adverse event profiles, and subsequent treatment outcomes. In this study, we determined the next treatment initiated 61 to 180 days after F‐LRT. The cumulative incidence of next treatment at 6 months was over 25% in patients who underwent TACE, RT, or HAIC, compared with around 10% in those following hepatectomy and ablation. These findings highlight the unmet medical needs in terms of early recurrence or progression, particularly in patients who undergo non‐curative‐intent LRT. For example, for TACE, the concept of “TACE refractory disease” is widely recognized [5] and evidence showing the benefit of upfront systemic therapy in patients with intermediate‐stage HCC [39] should penetrate further into clinical practice. The optimal strategy for non‐curative‐intent LRTs with peri‐LRT systemic therapy should be established based on emerging evidence from recently completed [19, 40, 41, 42, 43] and ongoing trials [44, 45, 46, 47], which should improve the outcomes in this setting. A recent real‐world study [48] revealed LRT‐dominant practice and gradual uptake of peri‐LRT systemic strategies following the introduction of immunotherapies, and further underscores the need for clearer protocols. The LRT‐dominant practice observed in this study aligns with the Japan Society of Hepatology 2021 guidance prioritizing LRT for early/intermediate stages and permitting repeated TACE until refractoriness [5]. By contrast, the more recent European Association for the Study of the Liver (EASL) guidelines (2024) emphasize earlier initiation of systemic therapy in patients with intermediate‐stage disease at high risk of TACE refractoriness, and integration with LRT [49]. Future studies should explore the ongoing evolution of LRT practices in Japan, including the adoption of EASL 2024 recommendations. This study has several limitations. Firstly, data on the detailed disease status (e.g., stage) which are essential factors for the choice of treatment, and the physician's intent for each treatment, could not be extracted from the MDV database. This may have led to misclassification of the treatment patterns, meaning “systemic therapy with LRT”—operationalized as LRT with PSysT and/or MT—cannot be definitively classified. Secondly, the population may include patients with disease recurrence > 2 years after previous LRT. However, we believe this can be justified because we can regard these diseases as the emergence of new lesions and the F‐LRT captured in this study represents the F‐LRT for new lesions. The disease status of early or intermediate HCC could be reset if the curative treatment was completed. Thirdly, continuous follow‐up was not possible due to deaths outside the hospital or switching hospitals. The short‐term outcomes (within 6 months around the F‐LRT) would help mitigate the limited follow‐up. Fourthly, as a descriptive study, the findings should not be interpreted as differences in outcome measures between LRTs. In other words, the findings of this study can only be interpreted as quantitative assessments within each group. To evaluate such differences, analyses with adjustment for confounding factors are required. Fifthly, the generalizability of our study may be limited. Since the MDV database is sourced from DPC‐participating hospitals, the study population cannot necessarily be regarded as a sample of all HCC patients who underwent F‐LRT in Japan. However, as many patients are expected to receive treatment at DPC‐participating hospitals, these findings are considered to partially reflect the status of HCC patients who underwent F‐LRT in Japan. Conclusion In conclusion, the results of this study suggest that PSysT was an emerging treatment option but not routinely performed in Japan in 2020–2022, and that LRT alone remained the standard approach for treating patients with HCC who received F‐LRT. The use of TACE with PSysT (with or without MT) slightly increased during the study period. The type and duration of the therapies used in combination with LRT varied, which suggests a lack of standardized protocols due to limited and non‐robust evidence. We believe a clear strategy is required to evaluate and establish appropriate combination therapies involving LRT for HCC, considering the unmet medical needs identified in this study. Author Contributions Junichi Shindoh: conceptualization, resources, supervision, writing – review and editing. Sachiyo Shirakawa: conceptualization, data curation, investigation, methodology, project administration, resources, validation, visualization, writing – review and editing. Ikumi Takashima: data curation, formal analysis, investigation, methodology, resources, validation, visualization, writing – original draft, writing – review and editing. Daisuke Kawai: data curation, formal analysis, investigation, methodology, resources, validation, visualization, writing – original draft, writing – review and editing. Kenichiro Nishida: data curation, formal analysis, investigation, methodology, project administration, resources, validation, visualization, writing – original draft, writing – review and editing. Hiroshi Kitagawa: conceptualization, resources, supervision, writing – review and editing. Funding This study, medical writing support, and publication fee were funded by AstraZeneca K.K. The sponsor contributed to study design, data collection, data analysis, and interpretation of the data, and reviewed the manuscript. Ethics Statement This study strictly adhered to the ethical principles established in the Declaration of Helsinki, Ethical Guidelines for Medical and Biological Research Involving Human Subjects, and Good Pharmacoepidemiology Practice (GPP). The Ethical Guidelines for Medical and Biological Research Involving Human Subjects exempt the need for ethical approval or informed consent for non‐interventional studies using data from a commercially available, de‐identified claims database. Nevertheless, the study protocol was duly approved by an independent, nonprofit ethics committee (MINS Institutional Review Board; approval number: MINS‐REC‐240206; date: March 6, 2025). Consent For this study, patient consent was not required. Conflicts of Interest Junichi Shindoh reported honoraria from Eisai and Chugai Pharmaceutical. Ikumi Takashima, Daisuke Kawai, Kenichiro Nishida, and Hiroshi Kitagawa are employees of AstraZeneca K.K. Ikumi Takashima holds stock in AstraZeneca. Sachiyo Shirakawa was an employee of AstraZeneca K.K. at the time of the study. Supporting information Table S1: LRT procedure codes. Table S2: Treatment information collected in each defined treatment period. Table S3: ATC and receipt codes for the systemic therapies. Table S4: Number and proportion of patients at each node in the Sankey diagram. Table S5: Treatment patterns. Table S6: Proportions of patients with a next treatment at 6 months according to the type of F‐LRT. Figure S1: Patient disposition.